🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Placebo to glycopyrronium bromide

Found 84 matching trials

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study was designed to investigate the 1 year efficacy and safety of th...

Status

Completed

Location

Novartis Investigative Site

Start Date

2009-06

Trial ID

NCT00929110

Treatments Being Tested

Glycopyrronium bromide Placebo to glycopyrronium bromide Tiotropium

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration

PHASE1

The purpose of this study is to evaluate the safety and the efficacy of Gly...

Status

Completed

Location

Medicines Evaluation Unit

Start Date

2010-08

Trial ID

NCT01176903

Treatments Being Tested

Glycopyrrolate Tiotropium placebo

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.

PHASE3

The study purpose is to evaluate the effect of QAB149 * NVA237 vs. QAB149 ...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-11

Trial ID

NCT01699685

Treatments Being Tested

QAB149 Placebo NVA237

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

PHASE3

The purpose of the study is to provide long term safety data of NVA237. Thi...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-10

Trial ID

NCT01697696

Treatments Being Tested

NVA237 Long-acting beta 2-agonist (LABA)Placebo

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to evaluate the efficacy of Fixed Combination ...

Status

Completed

Location

Medical Center Convex EOOD

Start Date

2018-06-15

Trial ID

NCT03590379

Treatments Being Tested

CHF 5993 DPI CHF5993 pMDI CHF 1535 pMDI Placebo DPI Placebo pMDI

Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

PHASE3

This study will assess of the efficacy and safety of a once-daily, 50µg inh...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-03

Trial ID

NCT01566604

Treatments Being Tested

NVA237 Placebo

Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers

PHASE1

This study will be carried out in healthy volunteers with the primary objec...

Status

Completed

Location

Clinical Pharmacology Unit - SGS Life Science Services

Start Date

2011-05

Trial ID

NCT01398111

Treatments Being Tested

Glycopyrrolate + Formoterol Glycopyrrolate Formoterol Placebo

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

PHASE1

The study is being conducted to compare the pharmacokinetic (PK) of BDP (an...

Status

Completed

Location

SGS Belgium NV - Clinical Pharmacology Unit

Start Date

2023-04-24

Trial ID

NCT05898984

Treatments Being Tested

Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

PHASE3

This study will investigate the effect of Budesonide, Glycopyrronium, and F...

Status

Completed

Location

Research Site

Start Date

2023-10-24

Trial ID

NCT06067828

Treatments Being Tested

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate Treatment B: Budesonide and Formoterol Fumarate Treatment C : Placebo

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

PHASE2

The purpose of this trial is to characterize the bronchodilator effects and...

Status

Completed

Location

Novartis Investigative Site

Start Date

2017-05-04

Trial ID

NCT03137784

Treatments Being Tested

NVA237 (glycopyrronium bromide)Placebo

Previous Next